Flow Pharma and OncoImmunity AS partner for the Development of FlowVax Personalized Cancer Vaccines

Flow Pharma Inc., a San Francisco Bay Area biotechnology company focused on developing personalized cancer vaccines, announced a collaboration with Norwegian bioinformatics company OncoImmunity AS.

Under the agreement OncoImmunity will license the Immuneoprofiler software to Flow Pharma to support the clinical development and commercialisation of products based on the FlowVax platform. The Immuneoprofiler™ has recently received the CE-IVD mark certification as a medical device, and fills some of the key gaps in neoantigen prediction. The FlowVax vaccine platform developed by Flow Pharma, is optimized to simultaneously deliver multiple neoantigen peptide targets to enhance tumor-specific killer T-cell attack. OncoImmunity will develop a customised machine-learning layer, using clinical data generated by Flow Pharma, that will work-in-sync with the Immuneoprofiler software to make predictions tailored to the FlowVax platform.

“This exciting partnership and licensing deal represents a fantastic opportunity for OncoImmunity to apply its Immuneoprofiler prediction software to the FlowVax technology in a clinical setting. It also affords OncoImmunity the opportunity to leverage its in-depth knowledge of immune-informatics and expertise in machine learning to develop a customised solution for the FlowVax platform that will support Flow Pharma’s needs now and in the years ahead” said Richard Stratford., Chief Executive Officer at OncoImmunity.

“We believe that OncoImmunity’s Immuneoprofiler software represents the best-in-class solution for predicting clinically relevant bona fide neoantigens. Flow Pharma’s bioinformatics team will be working closely with OncoImmunity AS to customize the way we utilize Immuneoprofiler in order to optimize the use of the data we will be generating” said Reid Rubsamen, M.D., CEO of Flow Pharma.